Investors Of Fulgent Genetics Stock May Have Legal Claims

Kehoe Law Firm, P.C. is investigating whether certain directors and/or officers of Fulgent Genetics, Inc. (“Fulgent,” “Fulgent Genetics” or the “Company”) (NASDAQ: FLGT) breached their fiduciary duties to Fulgent and its shareholders by making, or causing Fulgent to make, false and/or misleading statements, in addition to failing to disclose material adverse facts, about Fulgent’s business, operations, prospects, and financial health.
INVESTORS OF FULGENT GENETICS SINCE AT LEAST AUGUST 4, 2022 ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. 

The investigation concerns whether the board failed to disclose material information, including whether Fulgent misled investors by failing to disclose that (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; and (iii) Fulgent’s revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; and whether, as a result, statements about Fulgent’s business, operations, and prospects lacked a reasonable basis.

On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC was conducting an investigation into certain of Fulgent’s reports filed with the SEC from 2018 through the first quarter 2020.

The disclosure followed Fulgent’s receipt of a civil investigative demand issued by the U.S. Department of Justice “related to its investigation of allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and remuneration received or provided in violation of the Anti-Kickback Statute and the Stark Law.”

On this news, Fulgent’s stock price fell $11.02, or 17.29%, over the following two trading sessions, to close at $52.72 per share on August 8, 2022.

IF YOU HAVE BEEN INVESTED IN FULGENT GENETICS STOCK SINCE AT LEAST AUGUST 4, 2022, YOU ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AS YOU MAY HAVE LEGAL CLAIMS AGAINST THE DIRECTORS AND/OR OFFICERS OF THE COMPANY.   
INVESTORS OF FULGENT GENETICS SINCE AT LEAST AUGUST 4, 2022 ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected][email protected], TO DISCUSS THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

 Fulgent Genetics Breach of Fiduciary Duties Investigation - FLGT

Owners/Lessees of Mercedes Vehicles Equipped With an M274 Engine

Kehoe Law Firm, P.C. is investigating consumer claims on behalf of owners and  lessees of Mercedes vehicles equipped with an M274 engine. 

The investigation concerns an alleged defect regarding the pistons of the M274 engine which are prone to premature failure – an issue that may require the costly replacement of the entire engine.

According to the NHTSA:

The Office of Defects Investigation (“ODI”) received a petition dated April 29, 2022 requesting investigation of engine piston damage attributed to improperly sized wrist pins in the M274 engine found in the owner’s 2015 C300.

The petitioner reported that their MY 2015 Mercedes C300 vehicle lost power while driving at highway speeds accompanied by shaking, white smoke from the exhaust, and a burnt oil smell. Subsequent diagnosis at the dealership identified a cracked piston.

The petition alleges that all Mercedes-Benz models equipped with a variation of the M274 engine should be included in the evaluation and cites Mercedes TSB LI03.10-P-060916.

For additional information, please click NHTSA letter. 

Owners and Lessess of Mercedes-Benz vehicles, such as the Mercedes 2015 C300, equipped with an M274 engine are encouraged to contact Kehoe Law Firm, P.C., Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation evaluation of potential legal claims. 

Mercedes-Benz M274 Engine Defect Investigation

Investigation of NAVER’s Buyout of Poshmark – POSH

Kehoe Law Firm, P.C. is investigating whether the directors of Poshmark, Inc. (“Poshmark”) (NASDAQ: POSH) breached their fiduciary duties to its shareholders in approving a merger with NAVER Corporation (“NAVER”) for inadequate consideration.

The investigation concerns whether Poshmark’s board of directors failed to maximize the value of Poshmark for the benefit of Poshmark’s shareholders in connection with its announced merger with NAVER, in breach of their fiduciary duties to Poshmark’s shareholders, and whether Poshmark’s shareholders have suffered damages as a result.

On October 3, 2022, Poshmark announced it had reached an agreement to be bought out by NAVER for $17.90 per share. The transaction is valued at approximately $1.2 billion.

IF YOU INVESTED IN POSHMARK STOCK, YOU ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AS YOU MAY HAVE LEGAL CLAIMS AGAINST POSHMARK’S DIRECTORS AND OFFICERS. 
IF YOU WISH TO DISCUSS THIS INVESTIGATION, OR HAVE QUESTIONS ABOUT YOUR LEGAL RIGHTS, YOU ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected][email protected].

Investigation of NAVER Buyout of Poshmark - POSH

Enviva Inc. Investors May Have Legal Claims – EVA

Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Enviva Inc. (“Enviva”) (NYSE: EVA) breached their fiduciary duties to Enviva and its shareholders.

The investigation concerns whether members of Enviva’s board of directors or senior management failed to manage Enviva in an acceptable manner, in breach of their fiduciary duties, and whether Enviva and its shareholders have suffered damages as a result.

On October 12, 2022, Blue Orca Capital released a report stating that Enviva is overly reliant on capital raising to maintain its dividend, and that Enviva is engaging in “textbook greenwashing” regarding its wood pellet operations.

IF YOU INVESTED IN ENVIVA STOCK, YOU ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AS YOU MAY HAVE LEGAL CLAIMS AGAINST ENVIVA’S DIRECTORS AND OFFICERS. 
IF YOU WISH TO DISCUSS THIS INVESTIGATION, OR HAVE QUESTIONS ABOUT YOUR LEGAL RIGHTS, YOU ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected][email protected].

Securities Investigation on Behalf of Provident Bancorp Investors

Provident Bancorp Stock: PVBC Shareholders Are Encouraged To Contact Kehoe Law Firm, P.C. To Discuss Potential Legal Claims

Kehoe Law Firm, P.C. is investigating whether Provident Bancorp (NASDAQ: PVBC) and/or its officers and directors violated securities laws and/or breached their fiduciary duties to Provident Bancorp and its shareholders.

INVESTORS OF PROVIDENT BANCORP STOCK ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS ABOUT THEIR PVBC STOCK HOLDINGS. 

IF YOU ARE AN INVESTOR OF PROVIDENT BANCORP, YOU ARE ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO DISCUSS THE INVESTIGATION AND POTENTIAL LEGAL CLAIMS WITHOUT COST OR OBLIGATION.  

Securities Investigation on Behalf of Provident Bancorp Investors - PVBC